

# Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

NCT06577441

---

Status	RECRUITING
Phase	Phase 2
Sponsor	National Cancer Institute (NCI)
Enrollment	54 participants

## Key Eligibility Criteria

---

### Inclusion (32)

- GENERAL MYLEOMATCH REGISTRATION CRITERIA:
  - Patients must be registered to the Master Screening and Reassessment Protocol (MSRP) and assigned to this protocol by the MATCHBox Treatment Verification Team.
  - Participants must not have received prior anti-cancer therapy for AML or MDS.
  - Note: Hydroxyurea to control the white blood cell count (WBC) is allowed.
  - Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility.
- ... and 27 more (see full listing online)

## Locations (138 total)

---

Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States  
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States  
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States  
... and 135 more locations